Thermo Fisher Scientific has announced a strategic collaboration with SHL Medical aimed at delivering fully integrated drug device solutions for pharmaceutical and biotech companies. The partnership brings together Thermo Fisher’s capabilities in sterile fill finish and global manufacturing with SHL Medical’s expertise in advanced autoinjector systems.

As part of the agreement, Thermo Fisher is expanding its sterile fill finish and final assembly capacity in Ridgefield, New Jersey. This is expected to support growing demand for combination products, particularly in areas such as biologics and self administered therapies.

SHL Medical, known for its drug delivery technologies, will contribute device design and large scale autoinjector production capabilities. The collaboration is designed to streamline development timelines and simplify supply chains for customers seeking integrated solutions from drug substance through to final device assembly.

The companies aim to address increasing demand for patient friendly delivery systems, especially in chronic disease areas where self injection is becoming more common. By combining their respective strengths, the partners intend to accelerate time to market and improve efficiency across the drug development lifecycle.